CY1112138T1 - Αυτο-συντηρημενες υδατικες φαρμακευτικες συνθεσεις - Google Patents

Αυτο-συντηρημενες υδατικες φαρμακευτικες συνθεσεις

Info

Publication number
CY1112138T1
CY1112138T1 CY20111101200T CY111101200T CY1112138T1 CY 1112138 T1 CY1112138 T1 CY 1112138T1 CY 20111101200 T CY20111101200 T CY 20111101200T CY 111101200 T CY111101200 T CY 111101200T CY 1112138 T1 CY1112138 T1 CY 1112138T1
Authority
CY
Cyprus
Prior art keywords
compositions
amount
balanced
present
concentration
Prior art date
Application number
CY20111101200T
Other languages
English (en)
Inventor
Bhagwati P Kabra
Masood A Chowhan
L Wayne Schneider
Wesley Wehsin Han
Original Assignee
Alcon Research, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112138(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Research, Ltd. filed Critical Alcon Research, Ltd.
Publication of CY1112138T1 publication Critical patent/CY1112138T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Η παρούσα εφεύρεση απευθύνεται στην παραδοχή των αυτο-συντηρημένων οφθαλμικών συνθέσεων, πολλαπλών-δόσεων. Οι συνθέσεις κατέχουν επαρκή αντιμικροβιακή δραστηριότητα για να ικανοποιηθούν οι απαιτήσεις συντηρητικής αποτελεσματικότητας της USP (Φαρμακοποιία των Ηνωμένων Πολιτειών), ως επίσης και παρόμοιων συντηρητικών προτύπων (π.χ., τα ΕΡ και JP), χωρίς να απαιτείται η παρουσία συμβατικών αντι-μικροβιακών συντηρητικών παραγόντων, όπως είναι το χλωριούχο βενζαλκόνιο. Οι συνθέσεις συντηρούνται αποτελεσματικά μέσω ενός ισοσταθμισμένου ιονικού ρυθμιστικού συστήματος περιέχοντος ιόντα ψευδαργύρου σε μια συγκέντρωση των 0.04 έως 0.9 mM, κατά προτίμηση των 0.04 έως 0.4 mM. Μια άποψη του θέματος του ισοσταθμισμένου ρυθμιστικού συστήματος είναι ο περιορισμός της ποσότητας των ρυθμιστικών ανιόντων που εμφανίζονται σε μια συγκέντρωση των 15 mM ή λιγότερο, κατά προτίμηση των 5 mM ή λιγότερο. Σε μια προτιμώμενη ενσωμάτωση, οι συνθέσεις περιέχουν επίσης βορικό ή, το πλείστον κατά προτίμηση, ένα ή περισσότερα σύμπλοκα βορικού/πολυόλης. Η χρήση προπυλενγλυκόλης ως η πολυόλη σε τέτοια σύμπλοκα προτιμάται σθεναρά. Ο περιορισμός της ποσότητας των δισθενών μετάλλων άλλων από τον ψευδάργυρο και η ποσότητα των ιοντισμένων αλάτων που εμφανίζονται έχει επίσης προσδιοριστεί ότι είναι σημαντική στην μεγιστοποίηση της αντιμικροβιακής δραστηριότητας των ισοσταθμισμένων ρυθμιστικών συστημάτων.
CY20111101200T 2006-09-21 2011-12-02 Αυτο-συντηρημενες υδατικες φαρμακευτικες συνθεσεις CY1112138T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82652906P 2006-09-21 2006-09-21
US82741106P 2006-09-28 2006-09-28
EP07842914.9A EP2068822B2 (en) 2006-09-21 2007-09-20 Self preserved aqueous pharmaceutical compositions

Publications (1)

Publication Number Publication Date
CY1112138T1 true CY1112138T1 (el) 2015-11-04

Family

ID=39156274

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101200T CY1112138T1 (el) 2006-09-21 2011-12-02 Αυτο-συντηρημενες υδατικες φαρμακευτικες συνθεσεις

Country Status (22)

Country Link
US (3) US8268299B2 (el)
EP (1) EP2068822B2 (el)
JP (2) JP4785970B2 (el)
KR (1) KR101021933B1 (el)
AR (1) AR062929A1 (el)
AT (1) ATE531358T1 (el)
AU (1) AU2007299727B2 (el)
BR (1) BRPI0717067A2 (el)
CA (1) CA2606370C (el)
CL (1) CL2007002705A1 (el)
CY (1) CY1112138T1 (el)
DK (1) DK2068822T4 (el)
ES (1) ES2374444T5 (el)
HK (1) HK1126667A1 (el)
MX (1) MX2009002221A (el)
PL (1) PL2068822T5 (el)
PT (1) PT2068822E (el)
RU (1) RU2436568C2 (el)
SI (1) SI2068822T2 (el)
TW (1) TWI394564B (el)
UY (1) UY30605A1 (el)
WO (1) WO2008036847A2 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
JP5394927B2 (ja) 2006-09-28 2014-01-22 アルコン リサーチ， リミテッド 自己保存性水性医薬品組成物
TW200904485A (en) * 2007-05-18 2009-02-01 Alcon Res Ltd Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions
MX2010009336A (es) * 2008-03-17 2010-09-24 Alcon Res Ltd Composiciones farmaceuticas acuosas que contienen complejos de borato-poliol.
JP2009256281A (ja) * 2008-04-21 2009-11-05 Teika Seiyaku Kk イソプロピルウノプロストン含有点眼剤組成物
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
BRPI0923502A2 (pt) * 2008-12-22 2019-09-24 Alcon Res Ltd composições de soluções oculares tópicas para fornecer concentrações eficiêntes de agente ativo no segmento posterior do olho
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
KR20190049931A (ko) * 2009-12-15 2019-05-09 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 무자극성 안과용 포비돈-요오드 조성물
TW201127423A (en) * 2009-12-17 2011-08-16 Alcon Res Ltd Ophthalmic solutions with improved disinfection profiles
MX351584B (es) 2011-03-04 2017-10-20 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral.
CN103501775A (zh) * 2011-03-04 2014-01-08 格吕伦塔尔有限公司 他喷他多的胃肠外给药
JP6150510B2 (ja) * 2011-12-12 2017-06-21 ロート製薬株式会社 眼科用水性組成物
EP2630952A1 (en) 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
TW201417814A (zh) * 2012-09-28 2014-05-16 Otsuka Pharma Co Ltd 包括瑞巴派特之醫藥組成物
RU2675813C2 (ru) * 2013-02-15 2018-12-25 Сэндзю Фармацевтикал Ко., Лтд. Эмульсионная композиция дифлупредната, содержащая цинк
IL303425A (en) 2013-03-13 2023-08-01 Cour Pharmaceuticals Dev Company Secondary vaccine particles for the treatment of inflammation
EP3037094A1 (en) 2014-12-23 2016-06-29 Poifa Warszawa SA Ophthalmic pharmaceutical composition
RS58301B1 (sr) 2015-03-27 2019-03-29 Gruenenthal Gmbh Stabilne formulacije za parenteralnu primenu tapentadola
WO2017062770A1 (en) 2015-10-08 2017-04-13 Silverberg Noah Punctal plug and bioadhesives
US10632202B2 (en) 2016-03-04 2020-04-28 Johnson & Johnson Consumer Inc. Preservative containing compositions
AU2017329964B2 (en) 2016-09-23 2022-10-06 Grünenthal GmbH Stable formulation for parenteral administration of Tapentadol
WO2019123266A1 (en) 2017-12-20 2019-06-27 Novartis Ag Ophthalmic composition having a prostaglandin and a beta-blocker
IL295357A (en) 2020-02-06 2022-10-01 Ocular Therapeutix Inc Preparations and methods for the treatment of eye diseases
WO2023054669A1 (ja) 2021-09-30 2023-04-06 ロート製薬株式会社 眼科組成物
WO2024003078A1 (en) * 2022-06-27 2024-01-04 Warszawskie Zaklady Farmaceutyczne Polfa Sa Preservative-free ophthalmic composition comprising a prostaglandin analogue
EP4309644A1 (en) * 2022-07-22 2024-01-24 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Preservative-free ophthalmic composition comprising an antiglaucoma agent

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2084870B (en) 1980-10-10 1985-05-09 Muhlemann R Hans Oral compositions containing pyrimidine amine compounds and zinc salts
US5607698A (en) 1988-08-04 1997-03-04 Ciba-Geigy Corporation Method of preserving ophthalmic solution and compositions therefor
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US5221664A (en) 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
JP2875887B2 (ja) 1990-12-27 1999-03-31 アラーガン インコーポレイテッド コンタクトレンズの消毒法および消毒用組成物
US5460834A (en) 1991-12-13 1995-10-24 Alcon Laboratories, Inc. Combinations of polymers for use in physiological tear compositions
DK0639070T4 (da) * 1992-05-06 2010-12-13 Alcon Lab Inc Anvendelse af borat-polyolkomplekser til ophtalmiske præparater
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5320843A (en) 1992-12-10 1994-06-14 Polymer Technology Corporation Method for improving antibacterial properties of ophthalmic solutions
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
TW274516B (el) 1993-11-12 1996-04-21 Ciba Geigy Ag
AU3070395A (en) 1994-07-22 1996-02-22 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US6024954A (en) 1994-12-12 2000-02-15 Allergan Compositions and methods for disinfecting contact lenses and preserving contact lens care products
JP2997064B2 (ja) 1995-03-20 2000-01-11 ユニリーバー・ナームローゼ・ベンノートシヤープ 液体スキンクレンジング調合物
US5683993A (en) 1995-06-22 1997-11-04 Ciba Vision Corporation Compositions and methods for stabilizing polymers
HU225329B1 (en) * 1996-09-12 2006-09-28 Richter Gedeon Vegyeszet Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity
WO1998011867A1 (en) 1996-09-20 1998-03-26 Warner-Lambert Company Oral compositions containing a zinc compound
US5820822A (en) * 1996-10-25 1998-10-13 Kross; Robert D. Antimicrobial composition and method of use
ATE326983T1 (de) 1996-12-13 2006-06-15 Alcon Lab Inc Aminoalkohole enthaltende ophthalmische zusammensetzungen
US5858346A (en) 1997-05-09 1999-01-12 Allergan Compositions and methods for enhancing contact lens wearability
WO1999006023A1 (en) 1997-07-29 1999-02-11 Alcon Laboratories, Inc. Ophthalmic compositions containing galactomannan polymers and borate
US6034043A (en) 1999-04-20 2000-03-07 Lever Brothers Company, Division Of Conopco, Inc. Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US6166012A (en) 1999-07-30 2000-12-26 Allergan Sales, Inc. Antibiotic compositions and method for using same
AR031417A1 (es) 2000-11-29 2003-09-24 Novartis Ag Sistemas desinfectantes acuosos
AR035509A1 (es) * 2000-12-21 2004-06-02 Alcon Inc Solucion de lagrimas artificiales mejorada que contiene una combinacion de tres emolientes y el uso de dicha solucion para la fabricacion de un medicamento
JP4863589B2 (ja) 2001-09-28 2012-01-25 ロート製薬株式会社 水性組成物
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP2004339104A (ja) * 2003-05-14 2004-12-02 Rohto Pharmaceut Co Ltd 溶液の安定化方法
ES2561034T3 (es) 2003-12-09 2016-02-24 Novartis Ag Uso de bis-aminas para incrementar la actividad antimicrobiana de composiciones acuosas
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
AU2004305539B2 (en) 2003-12-11 2010-09-02 Alcon, Inc. Ophthalmic compositions containing a polysaccharide/borate gelling system
US20050214382A1 (en) 2004-03-29 2005-09-29 Erning Xia Zinc preservative composition and method of use
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US20070212420A1 (en) 2006-03-10 2007-09-13 Bausch & Lomb Incorporated Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
US20070297990A1 (en) 2006-06-27 2007-12-27 Shah Mandar V Self-preserving composition
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物

Also Published As

Publication number Publication date
EP2068822B2 (en) 2022-07-27
JP5411897B2 (ja) 2014-02-12
JP4785970B2 (ja) 2011-10-05
PL2068822T3 (pl) 2012-03-30
WO2008036847A3 (en) 2008-05-29
ES2374444T3 (es) 2012-02-16
EP2068822B1 (en) 2011-11-02
BRPI0717067A2 (pt) 2013-09-24
JP2011246476A (ja) 2011-12-08
ES2374444T5 (es) 2022-11-21
US8268299B2 (en) 2012-09-18
RU2009114849A (ru) 2010-10-27
US20110195132A1 (en) 2011-08-11
PT2068822E (pt) 2012-01-10
EP2068822A2 (en) 2009-06-17
SI2068822T1 (sl) 2012-02-29
CA2606370C (en) 2012-03-27
SI2068822T2 (sl) 2022-10-28
DK2068822T3 (da) 2012-01-23
PL2068822T5 (pl) 2022-11-14
MX2009002221A (es) 2009-03-13
UY30605A1 (es) 2008-03-31
JP2010504358A (ja) 2010-02-12
ATE531358T1 (de) 2011-11-15
AU2007299727A1 (en) 2008-03-27
CL2007002705A1 (es) 2008-05-16
CA2606370A1 (en) 2008-03-21
DK2068822T4 (da) 2022-10-31
AU2007299727B2 (en) 2011-10-06
TWI394564B (zh) 2013-05-01
AR062929A1 (es) 2008-12-17
US20080075790A1 (en) 2008-03-27
KR20090058567A (ko) 2009-06-09
KR101021933B1 (ko) 2011-03-16
HK1126667A1 (en) 2009-09-11
TW200820962A (en) 2008-05-16
WO2008036847A2 (en) 2008-03-27
AU2007299727A8 (en) 2009-04-09
US20130053440A1 (en) 2013-02-28
US8323630B2 (en) 2012-12-04
RU2436568C2 (ru) 2011-12-20

Similar Documents

Publication Publication Date Title
CY1112138T1 (el) Αυτο-συντηρημενες υδατικες φαρμακευτικες συνθεσεις
CY1117835T1 (el) Υδατικες φαρμακευτικες συνθεσεις που περιεχουν συμπλοκα βορικου - πολυολης
CY1123047T1 (el) Συνθεσεις που περιλαμβανουν δυσδιαλυτους στο νερο φαρμακευτικους παραγοντες και αντιμικροβιακους παραγοντες
CY1118428T1 (el) Ζιζανιοκτονα σκευασματα γλυφοσατης υψηλης ισχυος και χαμηλου ιξωδους
BR0317564A (pt) Compostos, composições e métodos para tratar doenças causadas por bactérias ou fungos
LTPA2016016I1 (lt) Azetinidai kaip mek inhibitoriai, skirti proliferacinių ligų gydymui
TW200612939A (en) Antibiotics containing borinic acid complexes and methods of use
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
CU23367A3 (es) Formulación de moxifloxacino con sal común
ZA200706530B (en) Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
HK1102702A1 (en) Anti-viral uses of borinic acid complexes
CY1114712T1 (el) Υδατικες φαρμακευτικες συνθεσεις περιεχουσες συμπλοκα βορικου-πολυολης
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
MX2008008556A (es) Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.
EA200800927A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
CY1110330T1 (el) Μυκητοκτονα μειγματα που περιεχουν boscalid και pyrimethanil
DK1392328T3 (da) Medikament til beskyttelse i radioterapi
EA200901443A1 (ru) Фунгицидные смеси
ATE543492T1 (de) Behandlung von lungenkrebs
EA200800780A1 (ru) Производные пиримидина и их применение в качестве открывателей калиевых каналов kcnq
EA200801215A1 (ru) Применение пираклостробина в качестве сафенера для тритиконазола при борьбе с вредными грибами
EA201000616A1 (ru) Фунгицидные соединения, способ их получения и их применение для борьбы с вредными грибами, а также содержащие их средства
AR043117A1 (es) Tratamiento de enfermedades bacterianas de los organos respiratorios
BR112013033060A2 (pt) solução oftálmica contendo ácido hialurônico ou sal deste e propileno glicol